SCHEMBL4226992

SCHEMBL4226992

CN1C(C)(C)CC(Oc2ccc(C(=O)O)cc2)CC1(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
SRD5A2 P31213 1/20 0.49
EPHX2 P34913 10/20 0.44
SRD5A1 P18405 1/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
FAAH O00519 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.40
CYP26A1 O43174 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP26B1 Q9NR63 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17274931 0.89 ALDH1A1 (0.41) ALDH1A1LMNACASP3SENP8SENP6
SCHEMBL19082599 0.88 SMN1; SMN2 (0.49) ALDH1A1LMNACASP3SENP8SENP6
SCHEMBL17287082 0.87 ELANE (0.46) ALDH1A1KMT2A
SCHEMBL17287080 0.87 PARP10 (0.56) ALDH1A1SENP8SENP6CA1CA2
SCHEMBL17274951 0.80 NAAA (0.39) CYP2C19CYP3A4
SCHEMBL17287083 0.80 SLC6A2 (0.50) LMNAKMT2A
SCHEMBL4237915 0.80 ALDH1A1 (0.55) ALDH1A1LMNACASP3SENP8SENP6
SCHEMBL1698633 0.79 CSF1R (0.53) ALDH1A1LMNATDP1RXRAKMT2A
SCHEMBL17287078 0.78 NAAA (0.49) EPHX2
SCHEMBL24214035 0.78 SENP8 (0.60) ALDH1A1LMNACASP3SENP8SENP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R ALDH1A1 4542/4885LMNA 2227/4885CASP3 3919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.